- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Prithviraj Bose Discusses Identifying Progression in Myelofibrosis
There are formal criteria to identify progression in myelofibrosis, but patients can progress in many different ways, said Prithviraj Bose, MD, of MD Anderson Cancer Center.
There are formal criteria to identify progression in myelofibrosis, but patients can progress in many different ways, said Prithviraj Bose, MD, of MD Anderson Cancer Center.
How do you identify progression in myelofibrosis?
Essentially there are the IWG-MRT [International Working Group-Myeloproliferative Neoplasms Research and Treatment] 2013 criteria that are kind of formal criteria for progression, but those are really to do with the spleen progression and to do with leukemic transformation, and pretty much that’s it.
However, in practice, a patient can progress in many ways. You can have the spleen grow; you can have symptoms worsen; you can have blood counts worsen, by which I mean more anemia, more thrombocytopenia; you can have the white blood cell count go up; and of course you can have the blasts go up and end up in accelerated or blastic phase, which is really the same as leukemic transformation.
So, it can be any of these things or more than one in combination, because you know patients don’t always progress in just one dimension.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
